Compare Nuwellis Inc (NUWE) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Thomson Reuters Corp — how do they compare? Nuwellis Inc trades at $0.8 (market cap $2.50M), while Thomson Reuters Corp trades at $97 (market cap $42.75B). The key difference: Thomson Reuters Corp is far larger — about 17100× Nuwellis Inc's market cap, and Thomson Reuters Corp pays a 2.65% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | TRI | |
|---|---|---|
Market Cap | $2.50M | $42.75B |
Sector | Technology | Industrials |
52-Week High | $164.50 | $173.48 |
52-Week Low | $0.73 | $76.55 |
Enterprise Value | -$1.21M | $45.37B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
Thomson Reuters (TRI) trades at $98.81, down 6.5% in 24 hours, with a bearish technical signal and support near $97. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance. Revenue grew 9% organically, with strong performance in Legal, Corporates, and Tax segments. Net income margin is 21.22%, and the P/E ratio is 26.03. Recent news highlights AI expansion with the launch of the proprietary Thomson-1 LLM and a cybersecurity incident affecting its case management system.
Outlook is mixed: robust recurring revenue and AI adoption support growth, but the stock faces near-term pressure from the price drop and cybersecurity risks. Analysts maintain a buy consensus with a $113 price target, implying 14% upside. Key risks include execution on AI initiatives, competitive pressures, and potential fallout from the security breach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
